Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hypertriglyceridemia~Exclusion Criteria:~* HbA1c \>/=9.0%, type 1 diabetes, or history of outpatient insulin use for more than 2 weeks in the last year~* Body mass index (BMI) \>40 kg/m2~* History of bariatric surgery or currently on weight loss drugs~* Use of oral contraceptives or hormone replacement therapy or statins unless stable for 3 months prior to dosing~* Group 1 and 2 patients: Use of systemic corticosteroids, fibrates, niacin, fish oil or other products containing omega-3 fatty acids within 6 weeks of dosing. Group 3 patients: unable to discontinue use of systemic corticosteroids at least 6 weeks prior to dosing ; use of niacin, fish oil, or other products containing omega-3 fatty acids unless on a stable well controlled dose for at least 30 days prior to screening that is not anticipated to change during the study period. Group 4 patients: unable to discontinue use of systemic corticosteroids at least 6 weeks prior to dosing; use of fibrates niacin, fish oil, or other products containing omega-3 fatty acids unless on a stable well controlled dose for at least 30 days prior to screening that is not anticipated to change during the study period.~* Use of topical corticosteroids, anticoagulants, or drugs or dietary supplements with potential lipid-altering effects unless dose is stable and well controlled for 30 days prior to dosing~* Any Screening laboratory values that are out of allowed reference ranges~* Inability to comply with protocol or study procedures~* Any other significant illness or condition that may adversely affect the subjects participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Non-extensive PK/non post-prandial
- Group 2a (Type: EXPERIMENTAL): Extensive PK
- Group 2b (Type: EXPERIMENTAL): Post-prandial assessment
- Group 3 (Type: EXPERIMENTAL): Stable dose of fibrate
- Group 4 (Type: EXPERIMENTAL): Fredrickson Type 1 dyslipidemia

Based on this trial design, predict the completion outcome and termination type (if applicable).